Literature DB >> 19337831

Activation of NMDA receptor is associated with up-regulation of COX-2 expression in the spinal dorsal horn during nociceptive inputs in rats.

Shu-Qin Li1, Yan-Li Xing, Wei-Na Chen, Shu-Ling Yue, Li Li, Wen-Bin Li.   

Abstract

Cyclooxygenases-2 (COX-2) in the spinal dorsal horn is up-regulated and plays an important role in pain and hyperalgesia induced by nociceptive stimulation. The mechanisms involved in the up-regulation of spinal COX-2 during nociceptive stimulation are yet not well understood. Because the important role of NMDA and its receptor in transmission of nociceptive information in the spinal cord, activation of the spinal NMDA receptor might contribute to the up-regulation of spinal COX-2 expression. The present study was undertaken to demonstrate the above hypothesis by observing changes of COX-2 expression in the spinal dorsal horn in rats subjected to formalin test and intrathecal administration of NMDA, a selective NMDA receptor agonist, in conditions with or without presence of MK-801, an antagonist of NMDA receptor, using methods of Western blotting, reverse transcription polymerase chain reaction and immunohistochemistry. The results showed that intrathecal injection of MK-801, a noncompetitive antagonist of NMDA receptor, significantly suppressed the up-regulation of the COX-2 expression and characteristic pain behavior responses evoked in formalin test. Whereas, intrathecal injection of NMDA significantly up-regulated the expression of COX-2 in the spinal dorsal horn in a time course corresponding to that of nociceptive behavioral responses elicited by the intrathecal NMDA administration. In addition, the up-regulation of the COX-2 expression induced by the intrathecal NMDA was dose-dependent and blocked by prior administration of MK-801. These findings proved that activation of NMDA receptor is associated with the up-regulation of COX-2 expression in the spinal dorsal horn during nociceptive stimulation in rats.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19337831     DOI: 10.1007/s11064-009-9932-9

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  45 in total

1.  Release of glutamate, nitric oxide and prostaglandin E2 and metabolic activity in the spinal cord of rats following peripheral nociceptive stimulation.

Authors:  G Vetter; G Geisslinger; I Tegeder
Journal:  Pain       Date:  2001-05       Impact factor: 6.961

2.  The role of cyclooxygenase-1 and -2 in the rat formalin test.

Authors:  Tatsuo Yamamoto; Natsuko Nozaki-Taguchi
Journal:  Anesth Analg       Date:  2002-04       Impact factor: 5.108

3.  GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury.

Authors:  Fei-Yue Zhao; Dave Spanswick; Jo C Martindale; Alison J Reeve; Iain P Chessell
Journal:  Pain       Date:  2006-10-19       Impact factor: 6.961

4.  Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E(2) release in the spinal cord.

Authors:  I Tegeder; E Niederberger; G Vetter; L Bräutigam; G Geisslinger
Journal:  J Neurochem       Date:  2001-11       Impact factor: 5.372

5.  Antisense oligonucleotides to N-methyl-D-aspartate receptor subunits attenuate formalin-induced nociception in the rat.

Authors:  Rus Yukhananov; Jane Guan; Gregory Crosby
Journal:  Brain Res       Date:  2002-03-15       Impact factor: 3.252

6.  Effect of endotoxin treatment on the expression and localization of spinal cyclooxygenase, prostaglandin synthases, and PGD2 receptors.

Authors:  Magdalena Grill; Akos Heinemann; Gerald Hoefler; Bernhard A Peskar; Rufina Schuligoi
Journal:  J Neurochem       Date:  2007-11-17       Impact factor: 5.372

7.  Role of cyclooxygenase 2 in acute spinal cord injury.

Authors:  D K Resnick; S H Graham; C E Dixon; D W Marion
Journal:  J Neurotrauma       Date:  1998-12       Impact factor: 5.269

8.  Extra-territorial pain in rats with a peripheral mononeuropathy: mechano-hyperalgesia and mechano-allodynia in the territory of an uninjured nerve.

Authors:  Michael Tal; Gary J Bennett
Journal:  Pain       Date:  1994-06       Impact factor: 6.961

9.  Gliosis alters expression and uptake of spinal glial amino acid transporters in a mouse neuropathic pain model.

Authors:  Carlo Cavaliere; Giovanni Cirillo; Maria Rosaria Bianco; Francesco Rossi; Vito De Novellis; Sabatino Maione; Michele Papa
Journal:  Neuron Glia Biol       Date:  2007-05

10.  P38 MAPK mediates COX-2 gene expression by corticosterone in cardiomyocytes.

Authors:  Haipeng Sun; Beibei Xu; Hiroyasu Inoue; Qin M Chen
Journal:  Cell Signal       Date:  2008-07-06       Impact factor: 4.315

View more
  5 in total

1.  Effects of neurosteroid actions at N-methyl-D-aspartate and GABA A receptors in the midbrain ventral tegmental area for anxiety-like and mating behavior of female rats.

Authors:  Cheryl A Frye; Jason J Paris
Journal:  Psychopharmacology (Berl)       Date:  2010-09-28       Impact factor: 4.530

2.  Interaction of PGHS-2 and glutamatergic mechanisms controlling the ovine fetal hypothalamus-pituitary-adrenal axis.

Authors:  Nathan Knutson; Charles E Wood
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-05-05       Impact factor: 3.619

Review 3.  The nociceptive and anti-nociceptive effects of bee venom injection and therapy: a double-edged sword.

Authors:  Jun Chen; William R Lariviere
Journal:  Prog Neurobiol       Date:  2010-06-15       Impact factor: 11.685

Review 4.  Clinical physiology and mechanism of dizocilpine (MK-801): electron transfer, radicals, redox metabolites and bioactivity.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2010 Jan-Feb       Impact factor: 6.543

5.  Protective effects of dexmedetomidine combined with flurbiprofen axetil on remifentanil-induced hyperalgesia: A randomized controlled trial.

Authors:  Zenggui Yu; Weilan Wu; Xiaodan Wu; Hongyi Lei; Cansheng Gong; Shiyuan Xu
Journal:  Exp Ther Med       Date:  2016-09-08       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.